Publications by authors named "Maria E Frolova"

Article Synopsis
  • - SARS-CoV-2, responsible for COVID-19, is rapidly evolving, making the development of effective and safe vaccines critical for public health, with the Betuvax-CoV-2 vaccine showing promise in previous trials.
  • - A study compared monovalent and bivalent vaccines' ability to neutralize different SARS-CoV-2 strains, revealing that while both types had strengths against certain variants, neither performed well against the Omicron BQ.1 strain at lower doses.
  • - The research implies that vaccine effectiveness relies on matching the formulation to the circulating SARS-CoV-2 strain, and using a bivalent vaccine doesn't necessarily provide an advantage over a monovalent vaccine for a single variant.
View Article and Find Full Text PDF

Unlabelled: COVID-19, being a life-threatening infection that evolves rapidly, remains a major public health concern calling for the development of vaccines with broad protection against different pathogenic strains and high immunogenicity. Aside from this, other concerns in mass immunization settings are also the scalability of production and relative affordability of the technology. In that regard, adjuvanted protein vaccines with particles mimicking the virus stand out among known vaccine technologies.

View Article and Find Full Text PDF

Public health threat coming from a rapidly developing COVID-19 pandemic calls for developing safe and effective vaccines with innovative designs. This paper presents preclinical trial results of "Betuvax-CoV-2", a vaccine developed as a subunit vaccine containing a recombinant RBD-Fc fusion protein and betulin-based spherical virus-like nanoparticles as an adjuvant ("Betuspheres"). The study aimed to demonstrate vaccine safety in mice, rats, and Chinchilla rabbits through acute, subchronic, and reproductive toxicity studies.

View Article and Find Full Text PDF

The COVID-19 pandemic is ongoing, and the need for safe and effective vaccines to prevent infection and to control spread of the virus remains urgent. Here, we report the development of a SARS-CoV-2 subunit vaccine candidate (Betuvax-CoV-2) based on RBD and SD1 domains of the spike (S) protein fused to a human IgG1 Fc fragment. The antigen is adsorbed on betulin adjuvant, forming spherical particles with a size of 100-180 nm, mimicking the size of viral particles.

View Article and Find Full Text PDF